Cue Biopharma (CUE) Amortization of Deferred Charges (2019 - 2025)
Cue Biopharma (CUE) has disclosed Amortization of Deferred Charges for 6 consecutive years, with $9000.0 as the latest value for Q4 2025.
- Quarterly Amortization of Deferred Charges changed 0.0% to $9000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36000.0 through Dec 2025, changed 0.0% year-over-year, with the annual reading at $37000.0 for FY2025, 0.0% changed from the prior year.
- Amortization of Deferred Charges hit $9000.0 in Q4 2025 for Cue Biopharma, roughly flat from $9000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $10000.0 in Q4 2022 to a low of $3000.0 in Q1 2022.
- Historically, Amortization of Deferred Charges has averaged $8704.4 across 4 years, with a median of $9000.0 in 2022.
- Biggest YoY gain for Amortization of Deferred Charges was 200.0% in 2023; the steepest drop was 7.29% in 2023.
- Year by year, Amortization of Deferred Charges stood at $10000.0 in 2022, then decreased by 7.29% to $9271.0 in 2023, then dropped by 2.92% to $9000.0 in 2024, then changed by 0.0% to $9000.0 in 2025.
- Business Quant data shows Amortization of Deferred Charges for CUE at $9000.0 in Q4 2025, $9000.0 in Q3 2025, and $9000.0 in Q2 2025.